Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Orazephin
- Development stage
- Unknown
- Lead developer
- ORxPharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Orazephin is an oral controlled-release small-molecule antibacterial drug being developed by ORxPharma. It is described by the company as a ceftriaxone-based cephalosporin formulation intended to deliver broad-spectrum antibacterial activity in an oral dosage form, with proposed uses in bacterial infections including meningitis and post-surgical prophylaxis. The product appears to represent a novel controlled-release formulation of ceftriaxone rather than a new molecular entity, and ORxPharma lists it in Phase 1 development.
- Brand names
- Orazephin
- Other names
- ceftriaxone oral controlled releaseoral ceftriaxone formulation
02
Targets
PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on Orazephin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orazephin.